Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
AssigneeCompass Pathfinder Limited
InventorsDerek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, Hemant Kashinath Patil, David E. Nichols
Life of this patent
Estimating the term…
Abstract
This invention relates to the large-scale production of psilocybin for use in medicine. Move particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
Claims27
A method of treating treatment resistant depression, the method comprising orally administering a therapeutically effective amount of an oral dosage form to a patient in need thereof, wherein the oral dosage form comprises:
- a crystalline Hydrate A of psilocybin characterized by XRPD peaks at 8.9±0.1, 13.8±0.1, 19.4±0.1, 23.1±0.1 and 23.5±0.1°2θ, wherein the psilocybin has a chemical purity of greater than 97% and no single impurity of greater than 1% as determined by HPLC analysis and a pharmaceutically acceptable excipient.
A method of treating treatment resistant depression, the method comprising administering a therapeutically effective amount of psilocybin to a patient in need thereof,
- wherein the psilocybin comprises a crystalline Hydrate A of psilocybin characterized by X-ray powder diffraction (XRPD) peaks at 8.9±0.1, 13.8±0.1, 19.4±0.1, 23.1±0.1 and 23.5±0.1°2θ, and
- wherein the psilocybin has a chemical purity of greater than 97% and no single impurity of greater than 1% as determined by HPLC analysis.
Dependencies are inferred from the claim text.